Increased mutagen sensitivity and DNA damage in pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 2, 2015, Pages 219-228

  Federici, Chiara ^a   Drake, Kylie M ^a   Rigelsky, Christina M ^a   McNelly, Lauren N ^a   Meade, Sirena L ^a   Comhair, Suzy A A ^a   Erzurum, Serpil C ^a   Aldred, Micheala A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

BMPR2; Dna damage; Genetic susceptibility; Reactive oxygen species

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ANTIOXIDANT; BLEOMYCIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CAV1 PROTEIN; DNA; EIF 2AK4 PROTEIN; ENG PROTEIN; ETOPOSIDE; GRISEOFULVIN; HISTONE H2AX; INITIATION FACTOR 2ALPHA; KCNK 3 PROTEIN; PROTEIN; REACTIVE OXYGEN METABOLITE; SMAD PROTEIN; SMAD9 PROTEIN; SUPEROXIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHEMOTHERAPY; CHROMOSOME ABERRATION; CHROMOSOME MUTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETER; FLOW CYTOMETRY; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEN PEROXIDE SCAVENGING ASSAY; MALE; MICRONUCLEUS TEST; MOLECULAR PATHOLOGY; MUTAGEN TESTING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNRELATED DONORS; BLOOD; GENETICS; LUNG; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY ARTERY;

CHROMOSOME ABERRATIONS; DNA DAMAGE; HUMANS; HYPERTENSION, PULMONARY; LUNG; PULMONARY ARTERY; REACTIVE OXYGEN SPECIES;

EID: 84938075246     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201411-2128OC     Document Type: Article

References (55)

1. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62: D42-D50.
2. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122: 164-172.
3. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122: 156-163.
4. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-S54.
5. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67:737-744.
6. The International PPH Consortium, Lane KB, Machado RD, Pauciulo M, Thomson JR, Phillips JA, 3rd, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-84.
7. Soubrier F, Chung WK, Machado R, Grunig E, Aldred MA, Geraci M, Loyd JE, Elliott CG, Trembath RC, Newman JH, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62:D13-D21.
8. Larkin EK, Newman JH, Austin ED, Hemnes AR, Wheeler L, Robbins IM, West JD, Phillips JA III, Hamid R, Loyd JE. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:892-896.
9. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998;101:927-934.
10. Tuder RM, Radisavljevic Z, Shroyer KR, Polak JM, Voelkel NF. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am J Respir Crit Care Med 1998;158: 1999-2001.
11. Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001;88:E2-E11.
12. Aldred MA, Comhair SA, Varella-Garcia M, Asosingh K, Xu W, Noon GP, Thistlethwaite PA, Tuder RM, Erzurum SC, Geraci MW, et al. Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182:1153-1160.
13. Drake KM, Comhair SA, Erzurum SC, Tuder RM, Aldred MA. Endothelial chromosome 13 deletion in congenital heart disease-associated pulmonary arterial hypertension dysregulates SMAD9 signaling. Am J Respir Crit Care Med 2015;191:850-854.
14. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014;129:786-797.
15. de Jesus Perez VA, Yuan K, Lyuksyutova MA, Dewey F, Orcholski ME, Shuffle EM, Mathur M, Yancy L Jr, Rojas V, Li CG, et al. Wholeexome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2014; 189:1260-1272.
16. Li M, Vattulainen S, Aho J, Orcholski M, Rojas V, Yuan K, Helenius M, Taimen P, Myllykangas S, De Jesus Perez V, et al. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2014;50:1118-1128.
17. Federici C, Aldred MA. Elevated levels of DNA damage in patients with pulmonary arterial hypertension measured by cytokinesis-block micronucleus assay [abstract]. Am J Respir Crit Care Med 2013;187: A5407.
18. Aldred MA, Federici C, McNelly LN, Comhair SA, Erzurum SC, Drake KM. Levels of DNA damage are systemically elevated in patients with pulmonary arterial hypertension and can be suppressed with N-acetylcysteine [abstract]. Am J Respir Crit Care Med 2014;189: A4769.
19. Comhair SA, Xu W, Mavrakis L, Aldred MA, Asosingh K, Erzurum SC. Human primary lung endothelial cells in culture. Am J Respir Cell Mol Biol 2012;46:723-730.
20. Aldred MA, Vijayakrishnan J, James V, Soubrier F, Gomez-Sanchez MA, Martensson G, Galie N, Manes A, Corris P, Simonneau G, et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat 2006;27:212-213.
21. Asosingh K, Aldred MA, Vasanji A, Drazba J, Sharp J, Farver C, Comhair SA, Xu W, Licina L, Huang L, et al. Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol 2008;172:615-627.
22. Bryce SM, Bemis JC, Avlasevich SL, Dertinger SD. In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. Mutat Res 2007;630:78-91.
23. Lane KL, Talati M, Austin E, Hemnes AR, Johnson JA, Fessel JP, Blackwell T, Mernaugh RL, Robinson L, Fike C, et al. Oxidative injury is a common consequence of BMPR2 mutations. Pulm Circ 2011;1: 72-83.
24. Fessel JP, Hamid R, Wittmann BM, Robinson LJ, Blackwell T, Tada Y, Tanabe N, Tatsumi K, Hemnes AR, West JD. Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulm Circ 2012;2:201-213.
25. Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169:764-769.
26. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, Janocha AJ, Masri FA, Arroliga AC, Jennings C, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA 2007;104:1342-1347.
27. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, Dyck JR, Gomberg-Maitland M, Thebaud B, Husain AN, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010;121: 2661-2671.
28. Fijalkowska I, Xu W, Comhair SA, Janocha AJ, Mavrakis LA, Krishnamachary B, Zhen L, Mao T, Richter A, Erzurum SC, et al. Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol 2010;176: 1130-1138.
29. Marsboom G, Wietholt C, Haney CR, Toth PT, Ryan JJ, Morrow E, Thenappan T, Bache-Wiig P, Piao L, Paul J, et al. Lung (1)(8)Ffluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;185:670-679.
30. Zhao L, Ashek A, Wang L, Fang W, Dabral S, Dubois O, Cupitt J, Pullamsetti SS, Cotroneo E, Jones H, et al. Heterogeneity in lung(18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. Circulation 2013;128:1214-1224.
31. Sutendra G, Michelakis ED. The metabolic basis of pulmonary arterial hypertension. Cell Metab 2014;19:558-573.
32. Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991;65:81-94.
33. Gorman A, McGowan A, Cotter TG. Role of peroxide and superoxide anion during tumour cell apoptosis. FEBS Lett 1997; 404:27-33.
34. Pham NA, Hedley DW. Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents. Exp Cell Res 2001;264:345-352.
35. Grigg A, Buchanan M, Whitford H. Late-onset pulmonary arterial hypertension in association with graft-versus-host disease after allogeneic stem-cell transplantation. Am J Hematol 2005;80: 38-42.
36. Limsuwan A, Pakakasama S, Rochanawutanon M, Hong-eng S. Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology 2006;105: 188-194.
37. Seguchi M, Hirabayashi N, Fujii Y, Azuno Y, Fujita N, Takeda K, Sato Y, Nishimura M, Yamada K, Oka Y. Pulmonary hypertension associated with pulmonary occlusive vasculopathy after allogeneic bone marrow transplantation. Transplantation 2000; 69:177-179.
38. Vaksmann G, Nelken B, Deshildre A, Rey C. Pulmonary arterial occlusive disease following chemotherapy and bone marrow transplantation for leukaemia. Eur J Pediatr 2002;161:247-249.
39. Bentur L, Cullinane C, Wilson P, Greenberg M, O'Brodovich H, Silver MM. Fatal pulmonary arterial occlusive vascular disease following chemotherapy in a 9-month-old infant. Hum Pathol 1991;22: 1295-1298.
40. Lombard CM, Churg A, Winokur S. Pulmonary veno-occlusive disease following therapy for malignant neoplasms. Chest 1987;92: 871-876.
41. Kramer MR, Estenne M, Berkman N, Antoine M, de Francquen P, Lipski A, Jacobovitz D, Lafair J. Radiation-induced pulmonary veno-occlusive disease. Chest 1993;104:1282-1284.
42. Schechter T, Leucht S, Bouffet E, Cutz E, Gassas A, Huang A, Bartels U, Humpl T, Doyle J. Pulmonary hypertensive vasculopathy following tandem autologous transplantation in pediatric patients with central nervous system tumors. Biol Blood Marrow Transplant 2013;19: 235-239.
43. Botros L, Van Nieuw Amerongen GP, Vonk Noordegraaf A, Bogaard HJ. Recovery from mitomycin-induced pulmonary arterial hypertension. Ann Am Thorac Soc 2014;11:468-470.
44. Attar H, Bedard K, Migliavacca E, Gagnebin M, Dupre Y, Descombes P, Borel C, Deutsch S, Prokisch H, Meitinger T, et al. Extensive natural variation for cellular hydrogen peroxide release is genetically controlled. PLoS One 2012;7:e43566.
45. de Haas EC, Zwart N, Meijer C, Nuver J, Boezen HM, Suurmeijer AJ, Hoekstra HJ, van der Steege G, Sleijfer DT, Gietema JA. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol 2008;26: 1817-1823.
46. Maffei F, Carbone F, Angelini S, Forti GC, Norppa H, Hrelia P. Micronuclei frequency induced by bleomycin in human peripheral lymphocytes: correlating BLHX polymorphism with mutagen sensitivity. Mutat Res 2008;639:20-26.
47. Gu J, Ye Y, Spitz MR, Lin J, Kiemeney LA, Xing J, Hildebrandt MA, Ki Hong W, Amos CI, Wu X. A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity. Hum Mol Genet 2011;20:820-826.
48. Surowy H, Rinckleb A, Luedeke M, Stuber M, Wecker A, Varga D, Maier C, Hoegel J, Vogel W. Heritability of baseline and induced micronucleus frequencies. Mutagenesis 2011;26:111-117.
49. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005;39:359-407.
50. Al Ghouleh I, Khoo NK, Knaus UG, Griendling KK, Touyz RM, Thannickal VJ, Barchowsky A, Nauseef WM, Kelley EE, Bauer PM, et al. Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. Free Radic Biol Med 2011;51:1271-1288.
51. Sugamura K, Keaney JF Jr. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 2011;51:978-992.
52. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol 2014;24:R453-R462.
53. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013;12:931-947.
54. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005;19: 1178-1180.
55. Masri FA, Xu W, Comhair SA, Asosingh K, Koo M, Vasanji A, Drazba J, Anand-Apte B, Erzurum SC. Hyperproliferative apoptosisresistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007;293: L548-L554.